Ephedrine Market Size, Share, Outlook, and Opportunity Analysis, 2022-2028
Ephedrine Market |
Decongestant and bronchodilator
ephedrine is used to treat bronchospasms brought on by asthma. The medication
helps the patient breathe more easily by reducing puffiness and constricting
blood vessels in the nasal passages, which opens up the lung airways. Ephedrine
is also frequently administered during spinal anaesthesia to minimise
intra-operative hypotension due to the drug's effects on the central nervous system.
The medication can be obtained as tablets, capsules, or injections.
The presence of numerous big and
small dealers makes the Ephedrine
Market extremely competitive. The level of competition among the
competitors in this market, according to the ephedrine market analysis research
report, is high. Vendors primarily compete on the basis of aspects including
pricing, user-friendliness, value-added advantages, and service benefits. Pfizer, Servier, Roche, Merck, Amgen,
Novartis, and Sanofi have to develop new concepts and technologies as well
as incorporate new technologies into their product portfolios in order to gain
a competitive advantage over the other players in the ephedrine service market.
Product Type Segmentation
·
Tablet
·
Capsule
·
Injection
Industry Segmentation
·
Medical use
·
Recreational
Regional Segmentation
·
North America (U.S. and Canada)
·
Latin America (Mexico, Brazil, Peru, Chile, and
others)
·
Western Europe (Germany, U.K., France, Spain,
Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
·
Eastern Europe (Poland and Russia)
·
Asia Pacific (China, India, Japan, ASEAN,
Australia, and New Zealand)
·
Middle East and Africa (GCC, Southern Africa,
and North Africa)
The Ephedrine Market expansion in the Europe
area is anticipated to be driven by an increase in ephedrine product launches.
For instance, the U.S. Food and Drug Administration granted approval to Avadel
Pharmaceuticals, formerly known as Flamel Technologies, in April 2016 for
Akovaz, an ephedrine sulphate injectable that will be used to treat hypotension
that happens after anaesthesia.
Additionally, the Asia Pacific
region's high prevalence of hypotension during spinal anaesthesia is predicted
to fuel the Ephedrine Market during
the anticipated time frame. For instance, a study that was published in the
Indian Journal of Anesthesia in 2018 found that 20%, 35%, and 40% of spinal
anesthesia-induced hypotension patients were mild, moderate, and severe,
respectively.
Comments
Post a Comment